Ctt Pharmaceutical Holdings Stock Current Valuation
| CTTH Stock | USD 0.06 0 6.19% |
Valuation analysis of CTT Pharmaceutical helps investors to measure CTT Pharmaceutical's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that CTT Pharmaceutical's price fluctuation is out of control at this time. Calculation of the real value of CTT Pharmaceutical is based on 3 months time horizon. Increasing CTT Pharmaceutical's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since CTT Pharmaceutical is currently traded on the exchange, buyers and sellers on that exchange determine the market value of CTT Pink Sheet. However, CTT Pharmaceutical's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.0637 | Real 0.0459 | Hype 0.06 | Naive 0.0641 |
The intrinsic value of CTT Pharmaceutical's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence CTT Pharmaceutical's stock price.
Estimating the potential upside or downside of CTT Pharmaceutical Holdings helps investors to forecast how CTT pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of CTT Pharmaceutical more accurately as focusing exclusively on CTT Pharmaceutical's fundamentals will not take into account other important factors: CTT Pharmaceutical Holdings Company Current Valuation Analysis
CTT Pharmaceutical's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current CTT Pharmaceutical Current Valuation | 18.87 M |
Most of CTT Pharmaceutical's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CTT Pharmaceutical Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, CTT Pharmaceutical Holdings has a Current Valuation of 18.87 M. This is 99.87% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The current valuation for all United States stocks is 99.89% higher than that of the company.
CTT Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CTT Pharmaceutical's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of CTT Pharmaceutical could also be used in its relative valuation, which is a method of valuing CTT Pharmaceutical by comparing valuation metrics of similar companies.CTT Pharmaceutical is currently under evaluation in current valuation category among its peers.
CTT Fundamentals
| Return On Equity | -4.49 | |||
| Return On Asset | -1.54 | |||
| Current Valuation | 18.87 M | |||
| Shares Outstanding | 21.32 M | |||
| Price To Earning | (3.00) X | |||
| Price To Book | 10.64 X | |||
| Revenue | 40 K | |||
| Net Income | (1.38 M) | |||
| Cash And Equivalents | 32.12 K | |||
| Total Debt | 87.62 K | |||
| Debt To Equity | 0.12 % | |||
| Current Ratio | 5.01 X | |||
| Book Value Per Share | 0.04 X | |||
| Cash Flow From Operations | (145.16 K) | |||
| Earnings Per Share | (0.08) X | |||
| Number Of Employees | 15 | |||
| Beta | 1.14 | |||
| Market Capitalization | 16.17 M | |||
| Total Asset | 186.54 K | |||
| Net Asset | 186.54 K |
About CTT Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CTT Pharmaceutical Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CTT Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CTT Pharmaceutical Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in CTT Pink Sheet
CTT Pharmaceutical financial ratios help investors to determine whether CTT Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in CTT with respect to the benefits of owning CTT Pharmaceutical security.